Here our utmost commitment is improving the quality of life for each and every individual. It is through this commitment that we constantly strive to innovate, improve and increase the availability of cost-efficient generic medicines to the global market.
Primus Ray Laboratories© has a commitment to mankind, a commitment of improving the quality of life for each and every individual through which we constantly strive to innovate, improve and increase the availability of cost-efficient generic medicines to the global market.
We believe that medicine should be available to all people regardless of their location, and affordable for them at any income level such that the cost of medical treatment should not be a concern for any part of the population.
Through our commitment we have chosen to focus our resources on generic medicines in which field we aim to increase the availability of our quality medicines and increase global awareness of the vast financial savings offered to society by making generic medicines available to the general population.
Hypogonadism is a condition in which the male testes or the female ovaries produce little or no sex hormones.
Hypogonadotropic hypogonadism (HH) is a form of hypogonadism that is due to a problem with the pituitary gland or hypothalamus.
Treatment depends on the source of the problem, but may involve:
Bronchology is the study and treatment of diseases of the tracheobronchial tree. The respiratory tree or tracheobronchial tree is a term also used to refer to the branching structure of airways supplying air to the lungs and includes the trachea, bronchi and bronchioles.
Usual diseases related to broncology are
Oncology is a branch of medicine that deals with tumors. Primus Ray Laboratories applies our world-renowned research and innovative treatments to deliver leading-edge and compassionate care for individuals with cancer.
Oncology is concerned with:
Nootropics also referred to as smart drugs, memory enhancers, neuro enhancers, cognitive enhancers, and intelligence enhancers, are drugs, supplements, nutraceuticals, and functional foods that improve one or more aspects of mental function, such as working memory, motivation, and attention.
At present, there are only a few drugs which have been shown to improve some aspect of cognition in medical reviews. Many more are in different stages of development. The most commonly used class of drug is stimulants.
These drugs are purportedly used primarily to treat cognitive or motor function difficulties attributable to such disorders as Alzheimer's disease, Parkinson's disease, Huntington's disease and ADHD
Thyroid gland makes and stores hormones that help regulate the heart rate, blood pressure, body temperature, and the rate at which food is converted into energy. Thyroid hormones are essential for the function of every cell in the body. They help regulate growth and the rate of chemical reactions (metabolism) in the body. Thyroid hormones also help children grow and develop.
The thyroid gland is located in the lower part of the neck, below the Adam's apple, wrapped around the trachea (windpipe). It has the shape of a butterfly: two wings (lobes) attached to one another by a middle part called the isthmus.
The thyroid uses iodine, a mineral found in some foods and in iodized salt, to make its hormones. The two most important thyroid hormones are thyroxine (T4) and triiodothyronine (T3).
Founded by a team of accomplished investment professionals with extensive and complementary industry backgrounds, Primus Ray Laboratories is a life sciences venture capital firm with a team that has a unique and long history of success in creating value. Deep relationships with thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Primus Ray Laboratories augments its core expertise of investing in biopharmaceuticals, specialty pharma and medical technology with the deep and diverse experience of the team in research and development, commercialization, business development and operations management at a global level. Primus Ray Laboratories has offices in Hong Kong, and Singapore.
Primus Ray Laboratories is a medical development company that intends to design, patent, and market medical products. Seven patents are initially incorporated. The company projects $16 million in sales in year three. The company expects to have $50 million in revenue by year five. Patent applications on its first three market entries have already been accomplished using a top patent law firm.
The mission of Primus Ray Laboratories is to design, develop, and market new patented technologies in the medical product field. The technologies will fill market niches that each account for a minimum of $20 million dollars in potential sales. Each technology will fill a current need in medical procedure by improving upon an existing technology or product, or by designing a product to serve a need that is clearly defined and acknowledged by medical professionals.
PRL approaches prototype development today with the same spirit as the original founders. Engineering and developing Medical product prototypes have long been apart of the company culture at PRL. Small and large companies and individuals have approached PRL to provide development services to assist in bringing an idea to the next stages in the product life cycle. Services offered include prototype engineering consulting, prototype design and fabrication, manufacturing, acquiring technical feedback and support, and assistance in aligning the product with distributors.
To measure, in a real-life setting, the benefits of using ready-to-use (RTU) injection preparations compared with conventional reconstituted admixtures (Admix) in terms of cost savings. DESIGN AND PERSPECTIVE: An economic model was developed, based on a randomised study. The perspective of the economic evaluation was that of the hospital administration. A microcosting approach was used to determine costs.
This study confirmed the potential for RTU forms to reduce nursing time associated with preparation and administration of intravenous admixtures and to enable overall cost savings.
Ready-to-use injection preparations versus conventional reconstituted admixtures: economic evaluation in a real-life setting.